

genOway's expertise selected as part of the AD-Inov consortium

New proprietary models dedicated to studies on Alzheimer's disease will be developed through this program supported by the Interministerial Fund

Lyon, France – September 10, 2009 - genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today announced its participation in the public-private AD-Inov program, selected by the Interministerial Fund (FUI) as part of its 8th call for entries.

Coordinated by Genfit, the AD-Inov program, whose budget amounts to 3.8 million EUR over 3 years, aims to develop new breakthrough technologies to support R&D and to identify new drugs that will fulfill unmet needs in Alzheimer's disease.

According to the program, genOway's mission is to develop new, relevant animal models to accelerate the discovery of candidate molecules exhibiting great therapeutic potential. The solutions developed should help improve the prediction of the molecules' path through and exposure to the central nervous system under both healthy and pathological conditions.

"We are always very proud of the recognition we receive for our know-how when dealing with ambitious collaborative programs. This is the case with AD-Inov since all partners are willing to find breakthrough solutions. For genOway, it is also an opportunity to provide new services to biopharmaceutical industries active in the field of central nervous system research - including Alzheimer's disease." **said Alexandre Fraichard, CEO of genOway**

About genOway

genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology Company developing genetically modified and high value added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the Company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, and supplies more than 250 customers. genOway is a leader in its market in terms of both size and customer portfolios. The Company's development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed many contracts with leaders of the pharmaceutical industry (Pfizer, Bayer, Boehringer Ingelheim, etc.), and with the most prestigious academic research centers (King's College and the University of Manchester in England, Duke University and the National Institutes of Health in the United States, the Institut Pasteur in France, NGFN and the Max Planck Institutes in Germany, etc.). To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents). For more information please consult www.genoway.com.

Press relations: Marie Norbert - genOway - info@genoway.com

Contact for investors: Gaëlle Lebel , CFO – info@genoway.com

Milestones - press & investors relations: Bruno Arabian / Jacques-Olivier Costa
Tel.: +33 (0)1 75 44 87 40 / 42 – E-mail: barabian@milestones.fr / jocosta@milestones.fr

Warning: This press release contains certain prospective statements, either express or implied, concerning genOway and its activities. These statements rely on certain risks, either known or unknown, uncertainties or other factors, that may lead to genOway's actual results, financial condition, performance or achievements differing significantly from the results, financial condition, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to updating the prospective statements contained therein, either as a result of new information, future events or any other occurrence. For a detailed description of the types of risks or uncertainties likely to cause a difference between genOway's actual results, financial condition, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" in the prospectus available on the genOway website: www.genoway.com.